Put patients at the center of everything.
At Alexion, patient centricity is not a slogan. It is a mindset embedded across the organization, from development through delivery. We partner with patients and caregivers to understand their lived experiences and incorporate those insights into decision-making. That commitment shapes how we think, how we work, and how we show up for the communities we serve.
For Advertising & Promotional Compliance teams, this creates a culture where success is measured not only by business impact, but by the ability to provide strategic guidance, uphold the highest ethical standards, and help ensure that patient-focused communications are accurate, compliant, and responsible.

The strength of Alexion. The scale of AstraZeneca. The opportunity to grow.
As part of AstraZeneca, Alexion combines deep rare disease expertise with the scale, infrastructure, and global reach of one of the world’s leading biopharmaceutical companies. It offers the best of both worlds: the agility and entrepreneurial spirit of a focused rare disease business, together with strong investment in innovation and broader opportunities for career development.
As Alexion grows, so do the opportunities for employees to grow with it. We emphasize professional development, capability building, and internal mobility, with access to learning experiences across both Alexion and AstraZeneca. That means the chance to deepen expertise in specialty and rare disease, contribute to launch excellence, build experience in a high-science, high-impact environment, and grow within a broader enterprise over time.
This is an opportunity to join a company with strong momentum in rare disease, where strategic thinking, compliance expertise, and a commitment to integrity play a critical role in advancing patient-focused innovation.
Join a company built on pioneering science.
Alexion has more than 30 years of rare disease leadership and more than 20 years of real-world evidence. Today, that legacy includes 6 US approved medicines across 7 rare diseases, with an ambition to deliver five new medicines globally by 2030. We are known for pursuing bold science in areas where progress has been limited, including a history of leadership in complement biology and a pipeline that spans multiple therapeutic areas such as hematology, nephrology, neurology, bone metabolism, endocrinology, and rare tumors.
